louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02097719: Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glaucoma
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2014-03-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This efficacy and safety study will evaluate LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL GFS, 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.


Eligibility criteria: Inclusion Criteria:

* Ocular hypertension or glaucoma that requires treatment with medication
* Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion Criteria:

* History of LASIK, LASEK, RK, and/or PRK in the study eye(s)
* History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months
* Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study

Primary outcomes:
measure: Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM
timeFrame: Week 12 at 8 AM, 12 PM, and 4 PM
Secondary outcomes:
Other outcomes:
Locations:
city: Racine
country: United States
state: Wisconsin
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01369719: Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
Official title: Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload Patients With β-Thalassemia and Intermediate Thalassemia in Bandarabbas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thalassemia
Iron Overload
Transfusion Related Complications
Keywords: Thalassemia
Iron overload
transfusion
osveral
desferal
Lead sponsor: Hormozgan University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-06-09
Enrollment: 138
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients. The aim of this study is to compare the efficacy and safety of osveral and desferal in transfusional iron overload patients with β-Thalassemia and intermediate Thalassemia in Bandarabbas.

Detailed description: This is a double blinded randomized controlled trial on Efficacy and safety of Osveral and Desferal in thalassemic patients.

Eligibility criteria: Inclusion Criteria:

* Confirmed intermedia or major thalassemia
* More then 2 years old
* Serum Ferritin level \> 1000
* Normal Creatinine and Complete Blood Count (CBC)

Exclusion Criteria:

* HCV, HBV or HIV positive patients

Primary outcomes:
measure: Ferritin level
timeFrame: 8 months
Secondary outcomes:
measure: Hemoglobin level
timeFrame: 8 month
measure: Drug side effects
timeFrame: 8 months
Other outcomes:
Locations:
city: Bandar abbas
country: Iran, Islamic Republic of
facility: Hormozgan University of Medical Sciences (HUMS)
state: Hormozgan
Study officials:
affiliation: Hormozgan University of Medical Sciences (HUMS)
name: Fariba Mansoori, Resident
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03954119: Blood Pressure in the Emergency Department
Official title: Prognostic Relevance of Elevated Blood Pressure in the Emergency Department
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Blood Pressure
Hypertension
Emergencies
Keywords: blood pressure
emergency department
atherosclerotic cardiovascular disease
myocardial infarction
stroke
long-term prognosis
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2019-05-17
Enrollment: 300272
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Unselected adult patients attending the ED irrespective of chief complaint

Brief summary: This is a cohort study based on a large sample (\> 600 000) of emergency department (ED) visits from two university hospital EDs. Information on incident disease after discharge from the ED will be collected through linkage to Swedish national in-patient register and cause of death register. The importance of blood pressure measured at the ED for incident atherosclerotic cardiovascular disease during long term follow up will be studied by Cox-regression analysis


Eligibility criteria: Inclusion Criteria:

* Attending the Emergency departments (ED) at Karolinska University hospital in Solna or Huddinge during the specified time period
* Record of blood pressure measurement from the ED-visit

Exclusion Criteria:

Primary outcomes:
measure: Incident Atherosclerotic Cardiovascular Disease (ASCVD)
timeFrame: 20161231
Secondary outcomes:
measure: Incident Myocardial infarction (MI)
timeFrame: 2016-12-31
measure: Incident All-cause stroke
timeFrame: 2016-12-31
measure: Incident Heart failure
timeFrame: 2016-12-31
measure: Incident chronic kidney disease (CKD)
timeFrame: 2016-12-31
Other outcomes:
Locations:
Study officials:
affiliation: Department of Clinical Science and Education, Södersjukhuset |
name: Per O Svensson, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Oras P, Habel H, Skoglund PH, Svensson P. Elevated Blood Pressure in the Emergency Department: A Risk Factor for Incident Cardiovascular Disease. Hypertension. 2020 Jan;75(1):229-236. doi: 10.1161/HYPERTENSIONAHA.119.14002. Epub 2019 Dec 2.
Clinical trial NCT04770519: Genetic Studies of Strabismus, Nystagmus, and Associated Disorders
Official title: Genetic Studies of Strabismus, Nystagmus, and Associated Disorders
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Strabismus
Nystagmus, Congenital
Keywords: strabismus
esotropia
exotropia
nystagmus
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
Collaborators: name: National Eye Institute (NEI)
First posted: 2021-02-25
Enrollment: 400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All willing members of families in which 3 or more biological relatives have strabismus (esotropia, exotropia, or vertical misalignments) with full eye movements, or affected individual has infantile esotropia or infantile nystagmus.

Brief summary: Strabismus (misalignment of the eyes) often runs in families. In this study, the investigators are looking for genetic variants associated with strabismus and nystagmus. Three types of subects will be enrolled: (1) Families with at least 3 members with strabismus, (2) individuals with infantile esotropia and their parents and siblings, and (3) individuals with infantile nystagmus and their parents. Whole exome and/or whole genome sequencing will be used to identify genetic variants shared by family members with strabismus and to identify genetic causes of nystagmus.


Eligibility criteria: Inclusion Criteria:

- Member of a family with at least 3 biological relatives with strabismus. (Both affected and non-affected family members will be enrolled).

OR

- Member of a family with at least 1 individual with infantile esotropia. (Both affected and non-affected family members will be enrolled).

OR

- Member of a family with at least 1 individual with infantile nystagmus. (Both affected and non-affected family members will be enrolled).

Exclusion Criteria:

* paralytic strabismus in affected family members

Primary outcomes:
measure: Genetic variants
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
Study officials:
affiliation: Assistant Professor
name: Mary Whitman, MD/PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01681719: Ergospirometric Values and WBV in Elderly
Official title: Whole Body Vibration as Alternative for Improve the Ergospirometric Values in Elderly: a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aging
Keywords: VO2
VCO2
VE/VO2
heart rate
Lead sponsor: Universidade Federal de Pernambuco
Sponsor class: OTHER
First posted: 2012-09-10
Enrollment: 25
Sex: ALL
Minimum age (years): 60
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: this study aims evaluate the ergospirometric values after 03 months of training with WBV in elderly health people. The hypothesis is increases of ergospirometric values.


Eligibility criteria: Inclusion Criteria:

* aged 60-74 years,
* Sedentary or Moderate A in accord with IPAQ short form (International Physical Activity Questionnaire) and those without disease.
* furthermore, the subjects should reach the ventilatory threshold 1, considered after meeting two of the following events:
* respiratory quotient (R) increases (R ≥1,1);
* loss of linearity between the pulmonary ventilation curve (VE) and oxygen consumption (VO2), plateau of VO2 or plateau of heart rate (HR) and increases of end-tidal PO2 (Pet O2)

Exclusion Criteria:

* Were excluded subjects with changes in Mini-mental state examination (MMSE) scores by age and educational level where the minimum score represents: illiterate 13 points, less than 8 study years is 18 points, 8 or more study years is 26 points 11.
* Were also excluded current smokers or previous, subjects with thrombosis, labyrinthitis, diabetes, hemodynamic instabilities, obesity, osteoporosis, neuromuscular diseases, pulmonary or cardiac diseases, changes in resting electrocardiogram or in exercise, ingestion of drugs to metabolism bone / muscle / heart chronotropism or with difficulties in adapting protocols

Primary outcomes:
measure: maximal O2 consumption
timeFrame: started and finished the protocol after 03 months
Secondary outcomes:
Other outcomes:
Locations:
city: Recife
country: Brazil
facility: UFPE
state: Pernambuco
Study officials:
References:
Clinical trial NCT02879019: Walking Training in Peripheral Artery Disease (GrEnADa Sub-study)
Official title: 12 Weeks of Walking Exercise Training in Women With Peripheral Artery Disease: A Sub-study of GrEnADa-project
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Peripheral Artery Disease
Intermittent Claudication
Lead sponsor: KU Leuven
Sponsor class: OTHER
First posted: 2016-08-25
Enrollment: 0
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Whereas the efficacy of exercise interventions has been abundantly proven in male with peripheral artery disease (PAD), it remains to be determined whether these interventions are effective in women. The aim of this randomized controlled trial which will be performed with 34 PAD women will be to investigating the effects of 12 weeks of supervised walking on functional capacity and cardiovascular function and regulation at rest and during exercise.


Eligibility criteria: Inclusion Criteria:

* aankle-brachial index (ABI) ≤ 0.9 in one or two legs
* fontaine stage II of PAD
* body mass index \<35 kg/m2
* resting systolic blood pressure (BP) \<160 mmHg and diastolic BP \<105 mmHg
* ability to walk at least 2min at 3.2 km/h
* ability to undertake an incremental treadmill test
* decrease of at least 15% in ABI after a maximal treadmill test
* not currently engaging in any regular exercise program

Exclusion Criteria:

* exercise induced signs of myocardial ischemia or complex ventricular arrhythmias
* cardiovascular autonomic neuropathy
* use of beta-blocker, nondihydropyridine calcium antagonists or insulin and hormone replacement therapy.

Primary outcomes:
measure: Change in walking capacity at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in functional capacity at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in heart rate pain threshold at 12 weeks of follow-up
timeFrame: 12 weeks
Secondary outcomes:
measure: Change in Ankle-Brachial Index decrease at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in ischemic window at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in autonomic modulation at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in cardiac output at 12 weeks of follow-up
timeFrame: 12 weeks
measure: Change in vascular function at 12 weeks of follow-up
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00602719: Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions
Official title: A Single Dose, Two-Period, Two-Treatment, 2-Way Crossover Bioequivalency Study of Zolpidem Tartrate Tablets 10 MG Under Fed Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Insomnia
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-01-28
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was the bioequivalence of a Roxane Laboratories' Zolpidem Tablets, 10 mg, to Ambien® Tablets, 10 mg (Sanofi-Synthelabo Inc.) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to Zolpidem or any comparable or similar product.

Primary outcomes:
measure: Bioequivalence
timeFrame: Baseline, Two period, Seven day washout
Secondary outcomes:
Other outcomes:
Locations:
city: Fargo
country: United States
facility: PRACS Institute, Ltd.
state: North Dakota
Study officials:
affiliation: PRACS Institute, Ltd.
name: Alan K Copa
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00444119: Survey in Patients With Chronic Adrenal Insufficiency in Germany
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adrenal Insufficiency
Addison's Disease
Keywords: adrenal insufficiency
subjective health status
quality of life
adrenal crisis
hormone replacement
DHEA
Lead sponsor: University of Wuerzburg
Sponsor class: OTHER
First posted: 2007-03-07
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The purpose of this survey is to assess patients with chronic primary or secondary adrenal failure regarding subjective health status, incidence and causes of adrenal crisis, hormone replacement regimens and concomitant endocrine or non endocrine disease.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years
* chronic adrenal failure with disease duration \> 12 months and hormone replacement therapy for cortisol deficiency

Exclusion Criteria:

* adrenal insufficiency due to adrenocortical carcinoma
* AI due to long-term pharmacological glucocorticoid treatment
* glucocortiocid doses above 7.5 mg prednisolone equivalent for other reasons than AI

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Dept of Medicine, Gastroenterology, Hepatology and Endocrinology, Charité Campus Mitte, Charité, University Medicine Berlin
city: Wuerzburg
country: Germany
facility: University of Wuerzburg, Dept of Medicine - Endocrine and Diabetes unit
Study officials:
affiliation: University of Wuerzburg
name: Bruno Allolio, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M, Decker O, Arlt W, Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007 Oct;92(10):3912-22. doi: 10.1210/jc.2007-0685. Epub 2007 Aug 7.
Clinical trial NCT01387919: Time Course and Nature of Nutrient Sensing During Fasting in Humans
Official title: Time Course and Nature of Nutrient Sensing During Fasting in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nutrient Sensing During a Prolonged Fast
Keywords: Set time points during 48 hours of fasting
Lead sponsor: Leiden University Medical Center
Sponsor class: OTHER
Collaborators: name: Centre for Medical Systems Biology
First posted: 2011-07-06
Enrollment: 12
Sex: MALE
Minimum age (years): 19
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Several studies have begun to determine the time course of events sensing energy availability in rodents. In contrast, there is not a single study that has examined this in humans to date. A better understanding of this energy sensing machinery in humans is of utmost importance to give us new insights into developing new therapies for common diseases such as obesity, diabetes mellitus, cardiovascular diseases and cancer. In these diseases, disturbances in the energy-sensing machinery possibly play a role. To determine the time course of energy sensing events in humans, the investigators will measure the concentration of various hormones in plasma, and biochemical changes in skeletal muscle at sequential time points during starvation in humans. The investigators choose to study the molecular machinery in muscle, since muscle is very sensitive to fuel deprivation.


Eligibility criteria: Inclusion Criteria:

* Healthy males
* Age 19-29 years old
* Body mass index (BMI) 19-25 kg/m2
* Stable weight for the last 3 months
* Caucasian
* Fasting plasma glucose (FPG) \< 6 mmol/L
* Well-controlled blood pressure (\< 150/95 mmHg)
* Creatinine \<100 umol/l
* Hb \> 7.5 mmol/l
* Negative family history (first degree) of type 2 diabetes mellitus (DM2)

Exclusion Criteria:

* Use of medication known to affect glucose metabolism (for example prednisone) or lipid metabolism
* Significant (chronic) disease
* Smoking (current)
* Alcohol consumption of more than 14 units per week at present or in the past
* Difficult accessible veins for insertion of an intravenous catheter
* Recent blood donation (within the last 3 months)
* Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year
* Rigorous exercise/sports 5 or more days a week

Primary outcomes:
measure: Change in several proteins/ribonucleic acid (RNA) from muscle biopsies upon fasting
timeFrame: 1.5h, 4h, 10h, 24h
Secondary outcomes:
measure: Change in several hormones, lipids etc. from blood samples upon fasting
timeFrame: 1.5h, 4h, 10h, 24h
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Leiden University Medical Center
state: Zuid-Holland
Study officials:
affiliation: Leiden University Medical Center
name: Hanno Pijl, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01386619: NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
Official title: Natural Killer Cell Selected T-cell Depleted Donor Lymphocyte Infusions (NK-DLI) in Patients After HLA-haploidentical Allogeneic Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes
Lymphoma
Neuroblastoma
Rhabdomyosarcoma
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2011-07-01
Enrollment: 15
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a phase I/II study of highly selected donor lymphocyte infusions in patients undergoing HLA-haploidentical hemopoietic stem cell transplantation. Patients will be offered "pre-emptive" NK-DLI early after HSCT.

Three schedules of NK-cell infusion will be studied: Basel patients (adult and pediatric) will receive NK-DLI on days +40 and +100 (pre-emptive-late); Frankfurt patients (pediatric) will receive NK-DLI on days +3, +40, and +100 (pre-emptive early). Patients not receiving pre-emptive NK-DLI with loss in donor chimerism or with evidence of minimal residual disease will be offered "therapeutic" NK-DLI.


Eligibility criteria: Inclusion Criteria:

* Patients with acute/chronic leukemia, myelodysplastic syndrome, lymphoid neoplasia, solid tumor or bone marrow failure syndrome
* signed informed consent of the patient (or his/her legal representative)

Exclusion Criteria:

* Patients with graft failure
* Patients with any grade of active acute of chronic graft-versus-host disease (GvHD)

Primary outcomes:
measure: Feasibility of NK-DLI production
timeFrame: At day of transplant (day 0)
measure: Safety of NK DLI Infusion
timeFrame: Day +60 after transplant
Secondary outcomes:
measure: Efficacy of NK DLI Infusions
timeFrame: 5 years after last NK DLI
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Universitätsklinikum
city: Basel
country: Switzerland
facility: University Hospital
Study officials:
affiliation: University Hospital, Basel, Switzerland
name: Jakob Passweg, MD
role: STUDY_CHAIR
affiliation: Johann Wolfgang Goethe University Hospital
name: Dirk Schwabe, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03025919: Evaluation of Innovated Screening Tools for Type 2 Diabetes Among Chinese Population(SENSIBLE STUDY I)
Official title: Using 2h-glycosuria Combined With Fasting Plasma Glucose , Advanced Glycation End-product Alone or in Combination With Fasting Plasma Glucose in Diabetes Screening in Chinese Natural Population
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type II Diabetes Mellitus
Keywords: Advanced glycation end-product
Glycosuria
Lead sponsor: Zhongda Hospital
Sponsor class: OTHER
First posted: 2017-01-20
Enrollment: 20000
Sex: ALL
Minimum age (years): 12
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Natural Chinese population

Brief summary: Evaluation of using 2h-UG combined with FPG, AGEsP alone or in combination with FPG in diabetes screening in Chinese natural population

Detailed description: Using the WHO criteria as the golden standard，drawing the ROC curve of 2h-UG combined with FPG, AGEsP alone or in combination with FPG，calculating the area under the ROC curve.

Eligibility criteria: Inclusion Criteria:

* 20\~70 year old urban and rural residents;
* Volunteer to participate in this study and sign informed consent.

Exclusion Criteria:

-

Primary outcomes:
measure: area under the ROC curve
timeFrame: 6 months
Secondary outcomes:
measure: sensitivity and specificity of screening
timeFrame: 6 months
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Southeast University
state: Jiangsu
Study officials:
References: